ReviewGene therapy2008
Toward exascale production of recombinant adeno-associated virus for gene transfer applications.
Review in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Advances in viral vector-based delivery systems for gene therapy: a comprehensive review.3 Biotech · 2025Review
- Quantification of full and empty particles of adeno-associated virus vectors via a novel dual fluorescence-linked immunosorbent assay.Molecular therapy. Methods & clinical development · 2024Article
- Mechanistic modeling explains the production dynamics of recombinant adeno-associated virus with the baculovirus expression vector system.Molecular therapy. Methods & clinical development · 2023Article
- Synthetic Biology Design as a Paradigm Shift toward Manufacturing Affordable Adeno-Associated Virus Gene Therapies.ACS synthetic biology · 2023Review
- Gene therapy for hemophilia.Hematology. American Society of Hematology. Education Program · 2022Review
- Application of Gene Therapy in Hemophilia.Current medical science · 2022Article
- Gene therapy for hemophilia.Hematology. American Society of Hematology. Education Program · 2019Review
- Development of Versatile and Flexible Sf9 Packaging Cell Line-Dependent OneBac System for Large-Scale Recombinant Adeno-Associated Virus Production.Human gene therapy methods · 2019Article
- Development of a Dual-Vector System Utilizing MicroRNA Mimics of theInternational journal of molecular sciences · 2019Article
- A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae.Molecular therapy. Methods & clinical development · 2018Article
- Molecular design for recombinant adeno-associated virus (rAAV) vector production.Applied microbiology and biotechnology · 2018Review
- Progress and challenges in viral vector manufacturing.Human molecular genetics · 2016Review
- Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.Biotechnology journal · 2015Review
- Successful transfection of genes using AAV-2/9 vector in swine coronary and peripheral arteries.The Journal of surgical research · 2012Article
- Recombinant adeno-associated viral vector production and purification.Methods in molecular biology (Clifton, N.J.) · 2012Article
- Article
- Fasting increases the in vivo gene delivery of AAV vectors.Clinical and translational science · 2010Article
- Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors.Gene therapy · 2010Article
- A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
To gain acceptance as a medical treatment, adeno-associated virus (AAV) vectors require a scalable and economical production method. Recent developments indicate that recombinant AAV (rAAV) production in insect cells is compatible with current good manufacturing practice production on an industrial scale. This platform can fully support development of rAAV therapeutics from tissue culture to small animal models, to large animal models, to toxicology studies, to Phase I clinical trials and beyond. Efforts to characterize, optimize and develop insect cell-based rAAV production have culminated in successful bioreactor-scale production of rAAV, with total yields potentially capable of approaching the exa-(10(18)) scale. These advances in large-scale AAV production will allow us to address specific catastrophic, intractable human diseases such as Duchenne muscular dystrophy, for which large amounts of recombinant vector are essential for successful outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.